Neuromuscular highlights - AAN 2005

Journal of Clinical Neuromuscular Disease

Volumn 7, Issue 4, 2006, Pages 206-209

  Cheema, Zahid ^a   Saperstein, David ^b   Jackson, Carolyn ^c   Newman, Daniel ^d  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b Neuromuscular Center Phoenix   (United States)

^c UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

AAN; Neuromuscular highlights

Indexed keywords

3,4 DIAMINOPYRIDINE; AMINOGLYCOSIDE DERIVATIVE; CANNABIS; EPHEDRINE; GABAPENTIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MEPREDNISONE; MEXILETINE; PTC 124; PYRIDOSTIGMINE; QUINIDINE; RILUZOLE; RITUXIMAB; STEROID; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; CARPAL TUNNEL SYNDROME; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG FATALITY; DRUG MEGADOSE; DUCHENNE MUSCULAR DYSTROPHY; ELECTROPHYSIOLOGY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FRONTAL LOBE; GASTROINTESTINAL SYMPTOM; GENOTYPE PHENOTYPE CORRELATION; HAND SURGERY; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LIMB; LONG QT SYNDROME; MYOTONIC DYSTROPHY; NERVE CONDUCTION; NERVE FIBER; NEUROMUSCULAR DISEASE; NEUROPATHIC PAIN; NONHUMAN; POLYNEUROPATHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SKIN BIOPSY; SYMPATHETIC TONE; ULNAR NERVE; UNITED STATES; UNSPECIFIED SIDE EFFECT; WARMING;

EID: 33749431400     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/01.cnd.0000211404.09693.7d     Document Type: Conference Paper

References (19)

1. Saconni S, Vilquin JT, Marolleau JP, et al. Myoblasts from affected and unaffected muscles of facioscapulohumeral muscular dystrophy (FSHD) patients display differences in morphology, proliferation and in vitro differentiation ability. Neurology. 2005;64(Suppl 1):413.
2. Barton E, Zadel M, Welch E, et al. PTC nonsense mutation suppression therapy of duchenne muscular dystrophy (DMD). Neurology. 2005;64(Suppl 1):176.
3. Hirawat S, Northcutt VJ, Welch EM et al. Phase 1 multiple dose safety and PK study of PTC 124 for nonsense mutation suppression therapy of duchenne muscular dystrophy (DMD). Neurology. 2005;64(Suppl 1):176.
4. Ropper A, Pieczek, Visnaw K. Vascular endothelial growth factor, gene transfer for diabetic neuropathy. Neurology. 2005;64(Suppl 1):53.
5. Iankovo E, Anguelov, Lewis R, et al. AAV-GDNF treatment of MPZ -/- Mice 53. Neurology. 2005;64(Suppl 1):53.
6. Hui AC-F, Wong SM, Soo Y, et al. Randomized controlled trial of surgical decompression versus steroid injection for the treatment of carpal tunnel syndrome. Neurology. 2005;64(Suppl 1):410.
7. Renaud S, Fuhr P, Gregor M, et al. High dose rituximab and anti-MAG-associated polyneuropathy. Neurology. 2005;64(Suppl 1):375.
8. Nurmikko TJ, Serpell MG, Hoggart B, et al. Oromucosal cannabis-based medicine (CBM) in the treatment of neuropathic pain characterized by allodynia. Neurology. 2005;64(Suppl 1):374.
9. Gibbons CH, Griffin JW, Polydefkis M, et al. The utility of skin biopsy in idiopathic sensory complaints. Neurology. 2005;64(Suppl 1):411.
10. Teoh HL, Wilder-Smith EP, Chow AYL, et al. Stimulated skin wrinkling in idiopathic small nerve fiber disease. A sensitive and simple screening test compared with other modalities of small nerve fiber function. Neurology. 2005;64(Suppl 1):216.
11. Ito T, Masanori K, Takashi WD, et al. High-resolution sonography of the peripheral nerves in neuropathy associated with necrotizing vacuities. Neurology. 2005;64(Suppl 1):373.
12. Van Asseldonk T, Berg LVd, Kalmijn S, et al. A rule for predicting the presence of chronic inflammatory demyelinating polyneuropathy. Neurology. 2005;64(Suppl 1):71.
13. Jarrar RG, Rubin DI, Reilly RL, et al. Electrophysiologic analysis of the effect of temperature on ulnar nerve conduction studies in patient with ulnar neuropathy at the elbow. Neurology. 2005;64(Suppl 1):287.
14. Brooks BR, Sanjak M, Roelke KA, et al. Phase 2B randomized dose-rangin clinical trial of tamoxifen: a non-steroidal tri-phenyl-ethylene selective estrogen receptor modulator (SERM) in amyotrophic lateral sclerosis (ALS). Increased survival in 20-30-40mg daily compared with 10mg weekly-10mg daily treatment cohorts. Neurology. 2005;64(Suppl 1):140.
15. MacGowan DJL, Scelsa SN, et al. A controlled study of reverse transcriptase detection in the serum and CSF of HIV negative sporadic ALS patients. Neurology. 2005;64(Suppl 1):428.
16. Burke G, Beeson DW, Newsome-Davis J, et al. Objective assessment of treatments in congenital myasthenic syndromes (CMS). Neurology. 2005;64(Suppl 1):290.
17. Martens WB, Moxley III RT, Logigian EL. Mexilitine: effective antimyotonia treatment in myotonic dystrophy type I (DM1). Neurology. 2005;64(Suppl 1):413.
18. Meola G, Sansone V, Gandossini S, et al. Progressive frontal lobe impairment in myotonic dystrophy type I (DM1) and type 2 (DM2): a longitudinal study. Neurology. 2005;64(Suppl 1):415.
19. Nguyen K, Bassez G, Eymard B, et al. Phenotypic and genetic analysis in a series of 55 patients with dyferlinopathy. Neurology. 2005;64(Suppl 1):413.